Genophrenix has identified several proteins and their genes that interact with a key component that is implicated in schizophrenia. By understanding which genes are involved in the disease and targeting these rather than attempting to treat the symptoms, Genophrenix believes that more specific and efficacious drugs can be developed with reduced side effects. Genophrenix will initially focus on developing targets and compounds to treat schizophrenia and aims to provide commercially viable licensing opportunities that will be attractive to the global pharmaceutical industry.